The histone variant H2A.X is a regulator of the epithelial-mesenchymal transition

Nature Communications

Volumn 7, Issue , 2016, Pages

  Weyemi, Urbain ^a   Redon, Christophe E ^a   Choudhuri, Rohini ^a   Aziz, Towqir ^a   Maeda, Daisuke ^a   Boufraqech, Myriem ^a   Parekh, Palak R ^a   Sethi, Taresh K ^a   Kasoji, Manjula ^a   Abrams, Natalie ^a   Merchant, Anand ^a   Rajapakse, Vinodh N ^a   Bonner, William M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; HISTONE H2A; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; H2AFX PROTEIN, HUMAN; HISTONE; HOMEODOMAIN PROTEIN; SNAI1 PROTEIN, HUMAN; SNAI2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SNAIL; ZEB1 PROTEIN, HUMAN;

CANCER; CELLS AND CELL COMPONENTS; CHEMICAL ALTERATION; DNA; GENE EXPRESSION; PROTEIN; TUMOR;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; COLON CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EXPERIMENTAL LUNG METASTASIS; EXPERIMENTAL METASTASIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ANIMAL; CANCER TRANSPLANTATION; CRISPR CAS SYSTEM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC VARIATION; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; METASTASIS; NUDE MOUSE; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CRISPR-CAS SYSTEMS; EPITHELIAL-MESENCHYMAL TRANSITION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENETIC VARIATION; HCT116 CELLS; HEK293 CELLS; HISTONES; HOMEODOMAIN PROTEINS; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; REAL-TIME POLYMERASE CHAIN REACTION; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTORS; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84958580752     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10711     Document Type: Article

References (67)

1. Tam, W. L., Weinberg, R. A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 19, 1438-1449 (2013).
2. Tsai, J. H., Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 27, 2192-2206 (2013).
3. Lamouille, S., Xu, J., Derynck, R. Molecular mechanisms of epithelialmesenchymal transition. Nat. Rev. Mol. Cell Biol. 15, 178-196 (2014).
4. Thiery, J. P., Acloque, H., Huang, R. Y., Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009).
5. Yao, D., Dai, C., Peng, S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 9, 1608-1620 (2011).
6. Chaffer, C. L., Thompson, E. W., Williams, E. D. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185, 7-19 (2007).
7. Malouf, G. G. et al. Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol. 14, R144 (2013).
8. Javaid, S. et al. Dynamic chromatin modification sustains epithelialmesenchymal transition following inducible expression of Snail-1. Cell Rep. 5, 1679-1689 (2013).
9. Jordan, N. V. et al. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Mol. Cell. Biol. 33, 3011-3025 (2013).
10. McDonald, O. G., Wu, H., Timp, W., Doi, A., Feinberg, A. P. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 18, 867-874 (2011).
11. Redon, C. et al. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 12, 162-169 (2002).
12. Biterge, B., Schneider, R. Histone variants: key players of chromatin. Cell Tissue Res. 356, 457-466 (2014).
13. Volle, C., Dalal, Y. Histone variants: the tricksters of the chromatin world. Curr. Opin. Genet. Dev. 25, 138 (2014).
14. Monteiro, F. L. et al. Expression and functionality of histone H2A variants in cancer. Oncotarget 5, 3428-3443 (2014).
15. Kapoor, A. et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 468, 1105-1109 (2010).
16. Bonner, W. M. et al. GammaH2AX and cancer. Nat. Rev. Cancer 8, 957-967 (2008).
17. Redon, C. E. et al. gamma-H2AX and other histone post-translational modifications in the clinic. Biochim. Biophys. Acta 1819, 743-756 (2012).
18. Bernstein, E., Hake, S. B. The nucleosome: a little variation goes a long way. Biochem. Cell Biol. 84, 505-517 (2006).
19. Sarma, K., Reinberg, D. Histone variants meet their match. Nat. Rev. Mol. Cell Biol. 6, 139-149 (2005).
20. Celeste, A. et al. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell 114, 371-383 (2003).
21. Vardabasso, C. et al. Histone variants: emerging players in cancer biology. Cell. Mol. Life Sci. 71, 379-404 (2014).
22. Celeste, A. et al. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 5, 675-679 (2003).
23. El-Haibi, C. P. et al. Critical role for lysyl oxidase in mesenchymal stem celldriven breast cancer malignancy. Proc. Natl Acad. Sci. USA 109, 17460-17465 (2012).
24. Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84-89 (2000).
25. Hajra, K. M., Chen, D. Y., Fearon, E. R. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613-1618 (2002).
26. Eger, A. et al. DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 24, 2375-2385 (2005).
27. Comijn, J. et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 7, 1267-1278 (2001).
28. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
29. Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117, 927-939 (2004).
30. Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
31. Kalluri, R., Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
32. Wels, C., Joshi, S., Koefinger, P., Bergler, H., Schaider, H. Transcriptional activation of ZEB1 by Slug leads to cooperative regulation of the epithelialmesenchymal transition-like phenotype in melanoma. J. Invest. Dermatol. 131, 1877-1885 (2011).
33. Marraffini, L. A., Sontheimer, E. J. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat. Rev. Genet. 11, 181-190 (2010).
34. Chen, W. T. et al. Systematic identification of functional residues in mammalian histone H2AX. Mol. Cell. Biol. 33, 111-126 (2013).
35. Zhang, P. et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat. Cell Biol. 16, 864-875 (2014).
36. Tan, E. J. et al. The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. Nucleic Acids Res. 43, 162-178 (2015).
37. Allan, R. S. et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature 487, 249-253 (2012).
38. Cedar, H., Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295-304 (2009).
39. Tie, F. et al. CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing. Development 136, 3131-3141 (2009).
40. Shlyueva, D., Stampfel, G., Stark, A. Transcriptional enhancers: from properties to genome-wide predictions. Nat. Rev. Genet. 15, 272-286 (2014).
41. Ocana, O. H. et al. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724 (2012).
42. Celia-Terrassa, T. et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122, 1849-1868 (2012).
43. Brabletz, T. To differentiate or not-routes towards metastasis. Nat. Rev. Cancer 12, 425-436 (2012).
44. Brabletz, T. EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22, 699-701 (2012).
45. Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580-584 (2013).
46. Kowalski, P. J., Rubin, M. A., Kleer, C. G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res. 5, R217-R222 (2003).
47. Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., Johnsen, S. A. Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer. Oncotarget 5, 2016-2029 (2014).
48. Stange, D. E. et al. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 59, 1236-1244 (2010).
49. Shike, M. et al. Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull. World Health Organ. 68, 377-385 (1990).
50. Armaghany, T., Wilson, J. D., Chu, Q., Mills, G. Genetic alterations in colorectal cancer. Gastrointest. Cancer Res. 5, 19-27 (2012).
51. Hanahan, D., Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
52. Puisieux, A., Brabletz, T., Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 16, 488-494 (2014).
53. Shaul, Y. D. et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell 158, 1094-1109 (2014).
54. Scheel, C. et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145, 926-940 (2011).
55. Wakefield, L. M., Hill, C. S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13, 328-341 (2013).
56. Sartor, M. A. et al. ConceptGen: a gene set enrichment and gene set relation mapping tool. Bioinformatics 26, 456-463 (2010).
57. Mannironi, C., Bonner, W. M., Hatch, C. L. H2A.X. a histone isoprotein with a conserved C-terminal sequence, is encoded by a novel mRNA with both DNA replication type and polyA 3' processing signals. Nucleic Acids Res. 17, 9113-9126 (1989).
58. Rodier, F. et al. DNA-SCARS: distinct nuclear structures that sustain damageinduced senescence growth arrest and inflammatory cytokine secretion. J. Cell. Sci. 124, 68-81 (2011).
59. Boufraqech, M. et al. miR30a inhibits LOX expression and anaplastic thyroid cancer progression. Cancer Res. 75, 367-377 (2015).
60. Faraji, F. et al. Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet. 8, e1002926 (2012).
61. Weyemi, U. et al. Intracellular expression of reactive oxygen species-generating NADPH oxidase NOX4 in normal and cancer thyroid tissues. Endocr. Relat. Cancer 17, 27-37 (2010).
62. Weyemi, U. et al. Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage. Radiat. Res. 183, 262-270 (2015).
63. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
64. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013).
65. Park, A., Won, S. T., Pentecost, M., Bartkowski, W., Lee, B. CRISPR/Cas9 allows efficient and complete knock-in of a destabilization domain-tagged essential protein in a human cell line, allowing rapid knockdown of protein function. PLoS ONE 9, e95101 (2014).
66. Jackstadt, R. et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J. Exp. Med. 210, 1331-1350 (2013).
67. Liu, J. et al. CCR6 is a prognostic marker for overall survival in patients with colorectal cancer, and its overexpression enhances metastasis in vivo. PLoS ONE 9, e101137 (2014).